Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript

Company Overview - Ultragenyx is a rare disease company focused on transformative treatments where none have existed in the past [2] - The company is 15 years old and is on a pathway to full year GAAP profitability in 2027 [2] - Ultragenyx has 4 current commercial programs that have significant and growing revenue [2] Upcoming Developments - The company has 3 near-term launches planned, including two gene therapies (401 program and 111 program) and an OI program (143) [3] - These upcoming programs are expected to transform the company [3] - The Angelman program is also a point of interest, receiving numerous inquiries [3]